Overcoming HCV treatment failure: From drug resistance to HCC: A case report
Keywords:
HCV, drug resistance, DAA, treatment failure, HCCAbstract
Chronic hepatitis C remains one of the leading causes of liver fibrosis progression, cirrhosis, and hepatocellular carcinoma. The introduction of direct-acting antiviral agents (DAAs) has significantly improved treatment outcomes, achieving a sustained virologic response (SVR) in most patients. However, in some cases, therapy fails due to the development of viral resistance, which is associated with mutations in therapy target regions of the viral genome.
This article presents a clinical case of HCV drug resistance to DAAs, analyzes the possible reasons for treatment failure and detection of HCV-induced HCC, and discusses management strategies for such patients in the context of modern molecular diagnostics and personalized therapy approaches.
References
1. Shen C, Jiang X, Li M, Luo Y. Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers (Basel). 2023 Jan 15;15(2):533. doi: 10.3390/cancers15020533.
2. Musabaev E, Estes C, Sadirova S, et al. Viral hepatitis elimination challenges in low- and middle-income countries-Uzbekistan Hepatitis Elimination Program (UHEP). Liver Int. 2023 Apr;43(4):773-84. doi: 10.1111/liv.15514. Erratum in: Liver Int. 2024 Jan;44(1):266. doi: 10.1111/liv.15652.
3. Lynch EN, Russo FP. Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals. J Clin Med. 2023 Mar 12;12(6):2195. doi: 10.3390/jcm12062195.
4. Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1197-209. doi: 10.1080/17425255.2016.1209484.
5. Kishida Y. Mechanisms of virologic failure in hepatitis C and strategies for treatment failure. MOJ Immunol. 2016;4(1):00114. doi: 10.15406/moji.2016.04.00114.
6. Chauke GD, Nakwafila O, Chibi B, Sartorius B, Mashamba-Thompson T. Factors influencing poor medication adherence amongst patients with chronic disease in low-and-middle-income countries: A systematic scoping review. Heliyon. 2022 Jun 15;8(6):e09716. doi: 10.1016/j.heliyon.2022.e09716.
7. Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat. 2018 Mar:37:17-39. doi: 10.1016/j.drup.2018.01.004.
8. Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017 Jun;142:83-122. doi: 10.1016/j.antiviral.2017.02.014.
9. Yu W, Ling T, Bin H, et al. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. J Med Chem. 2016 Nov 23;59(22):10228-43. doi: 10.1021/acs.jmedchem.6b01234.
10. Liu Z, Mao X, Wu J, et al. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1906-14.e25. doi: 10.1016/j.cgh.2019.10.046.
11. Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. 2021 Feb;74(2):458–65. doi: 10.1016/j.jhep.2020.10.016.
12. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012 Feb;32 Suppl 1(01):151-6. doi: 10.1111/j.1478-3231.2011.02706.x.
13. Bartenschlager R, Baumert TF, Bukh J, et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res. 2018 Mar 15:248:53-62. doi: 10.1016/j.virusres.2018.02.016.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Evgeniya Kazakova, Nargiz Ibadullaeva, Umed Ismoilov, Bekzod Umurzakov, Erkin Musabaev
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
